RedHill Biopharma Ltd. (RDHL) Cash Flow Statement
Where RDHL’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$9.7M
- Capital expenditures
- $5,000 1.7% of revenue
- Free cash flow
- −$9.7M −3,376.2% margin
- Returned to shareholders
- —
- Change in cash
- −$646,000 cash at year-end $4.0M
Cash from operations
−$9.7M
Acquisitions & other
+$1.7M
Net borrowing (repayment)
−$447,000
Shares issued
+$7.8M
Change in cash
−$646,000
Drawn to scale: where the cash came from and how it was used. Hover for values.
RDHL operating cash flow, capex and free cash flow
Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)
RDHL cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$28.3M2016 | −$9.7M2025 | — | |
| Capital expenditures | $120,0002016 | $5,0002025 | −29.8%/yr | |
| Free cash flow | −$28.4M2016 | −$9.7M2025 | — | |
| Free cash flow margin | −28,097.0%2016 | −3,376.2%2025 | +24,720.8 pts | |
| Stock-based compensation | $1.7M2016 | $457,0002025 | −13.5%/yr | |
| Share buybacks (net) | $02016 | $02019 | — | |
| Capex / revenue | 118.8%2016 | 1.7%2025 | −117.1 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
RDHL cash flow by activity
OperatingInvestingFinancingChange in cash
RDHL net income vs operating cash flow
Net incomeOperating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
RDHL cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$429,000 | −$8.3M | $23.9M | −$71.7M | −$97.7M | −$76.2M | −$42.3M | −$38.8M | −$45.5M | −$29.4M |
| Depreciation & amortization | $409,000 | $619,000 | $2.0M | $8.2M | $18.1M | $8.7M | $1.2M | $90,000 | $81,000 | $44,000 |
| Stock-based compensation | $457,000 | $665,000 | $1.6M | $5.7M | $10.2M | $4.2M | $3.0M | $2.7M | $2.2M | $1.7M |
| Change in working capital | −$2.0M | $2.1M | −$15.6M | $8.0M | −$1.2M | $8.4M | −$2.3M | $1.4M | $3.7M | $553,000 |
| Other non-cash items | −$8.1M | −$4.4M | −$47.8M | $20.6M | $5.5M | $6.2M | −$347,000 | $171,000 | −$5.2M | −$1.2M |
| Cash from operating activities | −$9.7M | −$9.4M | −$35.8M | −$29.2M | −$65.0M | −$48.6M | −$40.7M | −$34.5M | −$44.8M | −$28.3M |
| Investing activities | ||||||||||
| Capital expenditures | −$5,000 | −$9,000 | −$11,000 | −$198,000 | −$115,000 | −$53.8M | −$203,000 | −$58,000 | −$1.2M | −$120,000 |
| Investments (net) | $0 | −$9,000 | $4,000 | $8.3M | −$8.0M | −$35.6M | $5.2M | $5.4M | −$18.6M | $24.5M |
| Acquisitions & other investing | $1.7M | $9,000 | $10,989 | $198,000 | $0 | $53.8M | $203,000 | $58,000 | $1.2M | $120,000 |
| Cash from investing activities | $1.7M | −$9,000 | $3,989 | $8.3M | −$8.1M | −$35.6M | $5.2M | $5.4M | −$18.6M | $24.5M |
| Financing activities | ||||||||||
| Share repurchases & issuance (net) | — | — | — | — | — | — | $36.3M | $42.3M | $25.7M | $36.0M |
| Net borrowing (repayment) | −$447,000 | −$636,000 | −$1.2M | −$1.5M | −$1.7M | $76.5M | −$796,000 | −$796,000 | −$796,000 | −$796,000 |
| Shares issued | $7.8M | $8.3M | $14.0M | $23.8M | $78.5M | $23.9M | $36.3M | $41.9M | $0 | $0 |
| Other financing | $0 | $790,000 | $8.6M | −$10.9M | −$3.4M | −$15.9M | −$36.3M | −$41.6M | $796,000 | $796,000 |
| Cash from financing activities | $7.3M | $8.4M | $21.4M | $11.5M | $73.5M | $84.4M | $35.5M | $41.8M | $25.7M | $36.0M |
| Summary | ||||||||||
| Net change in cash | −$646,000 | −$952,000 | −$14.4M | −$9.5M | $179,000 | $272,000 | $18,000 | $12.6M | −$37.3M | $32.3M |
| Cash at end of period | $4.0M | $4.6M | $5.6M | $20.0M | $29.5M | $29.3M | $29.0M | $29.0M | $16.5M | $53.8M |
| Free cash flow | −$9.7M | −$9.4M | −$35.8M | −$29.4M | −$65.2M | −$102.4M | −$41.0M | −$34.5M | −$46.0M | −$28.4M |
| Free cash flow margin | −3,376.2% | −116.6% | −548.7% | −47.5% | −76.0% | −159.0% | −651.0% | −412.9% | −1,146.7% | −28,097.0% |
| Capex / revenue | 1.7% | 0.1% | 0.2% | 0.3% | 0.1% | 83.6% | 3.2% | 0.7% | 29.5% | 118.8% |
| Operating cash flow / net income | — | — | −1.50 | — | — | — | — | — | — | — |
| Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | |||||||||||
| Net income | −$2.1M | −$2.1M | −$2.6M | −$1.5M | −$1.5M | −$13.5M | $761,000 | −$3.7M | −$3.7M | −$35.7M | −$11.7M |
| Depreciation & amortization | $84,000 | $84,000 | $100,500 | $209,000 | $209,000 | $202,500 | −$58.9M | $2.0M | $2.0M | $2.1M | $1.9M |
| Stock-based compensation | $148,500 | $148,500 | $218,000 | $114,500 | $114,500 | $399,000 | $705,000 | $1.1M | $1.1M | $1.6M | $618,000 |
| Change in working capital | −$144,500 | −$144,500 | $451,500 | $1.6M | $1.6M | −$3.7M | $638,000 | $4.2M | $4.2M | $342,000 | −$5.4M |
| Other non-cash items | −$529,000 | −$529,000 | $228,000 | −$3.5M | −$3.5M | $7.6M | $46.2M | −$6.1M | −$6.1M | $25.6M | −$2.0M |
| Cash from operating activities | −$2.5M | −$2.5M | −$1.6M | −$3.1M | −$3.1M | −$9.0M | −$10.6M | −$2.4M | −$2.4M | −$6.0M | −$16.6M |
| Investing activities | |||||||||||
| Capital expenditures | −$2,000 | −$2,000 | −$4,000 | −$500 | −$500 | −$2,000 | −$7,000 | −$1,335 | $0 | −$22,000 | −$163,000 |
| Investments (net) | — | — | — | — | — | — | −$7,000 | $0 | $0 | −$22,000 | −$163,000 |
| Acquisitions & other investing | $0 | $0 | $0 | $0 | $0 | $7,500 | $7,000 | −$8.5M | — | $22,000 | $163,000 |
| Cash from investing activities | −$2,000 | −$2,000 | −$4,000 | −$500 | −$500 | $5,500 | −$7,000 | −$8.5M | — | −$22,000 | −$163,000 |
| Financing activities | |||||||||||
| Dividends paid | — | — | — | — | — | — | −$1.6M | — | — | — | — |
| Share repurchases & issuance (net) | — | — | — | — | — | — | −$1.6M | — | — | — | — |
| Net borrowing (repayment) | — | — | — | — | — | — | — | — | — | −$621,000 | −$355,000 |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $6.7M | $7.6M | $0 | $15.5M |
| Other financing | $1.6M | $1.6M | $258,500 | $4.0M | $4.0M | $8.3M | $3.2M | $493,000 | −$384,000 | −$5.1M | −$236,000 |
| Cash from financing activities | $1.6M | $1.6M | $258,500 | $4.0M | $4.0M | $8.3M | $3,000 | $7.2M | $7.2M | −$5.7M | $14.9M |
| Summary | |||||||||||
| Net change in cash | — | — | −$7.3M | $7.3M | — | −$7.0M | −$10.6M | $4.8M | $4.8M | −$11.8M | −$1.9M |
| Cash at end of period | — | — | — | $7.3M | — | $7.0M | $7.0M | $20.0M | $20.0M | $15.2M | $27.0M |
| Free cash flow | −$2.5M | −$2.5M | −$1.6M | −$3.1M | −$3.1M | −$9.0M | −$10.6M | −$2.4M | −$2.4M | −$6.0M | −$16.7M |
| Free cash flow margin | −123.0% | −123.0% | −58.3% | −240.5% | −240.5% | −1,590.2% | −590.0% | −18.9% | −18.9% | −34.5% | −91.3% |
| Capex / revenue | 0.1% | 0.1% | 0.1% | 0.0% | 0.0% | 0.4% | 0.4% | 0.0% | 0.0% | 0.1% | 0.9% |
| Operating cash flow / net income | — | — | — | — | — | — | −13.91 | — | — | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
RDHL cash generation
In fiscal 2025 (ended December 31, 2025), RedHill Biopharma generated -$9.7 million of cash from operations and spent $0.0 million on capital expenditures, leaving free cash flow of -$9.7 million, −3,376.2% of revenue. Cash and equivalents fell by $0.6 million over the year.
Related: RDHL income statement, RDHL balance sheet. See the RDHL stock overview for the latest quote and news.
RDHL cash flow FAQ
What is RedHill Biopharma's free cash flow?
RedHill Biopharma's free cash flow was -$9.7 million in fiscal 2025: -$9.7 million of operating cash flow minus $0.0 million of capital expenditures It was -$9.4 million a year earlier..
How much cash does RedHill Biopharma generate from operations?
RedHill Biopharma generated -$9.7 million of cash from operating activities in fiscal 2025.
How much does RedHill Biopharma spend on capital expenditures?
RedHill Biopharma spent $0.0 million on capital expenditures in fiscal 2025, 1.7% of revenue, compared with $0.0 million the year before.